logo-loader

Oncolytics says survival rate boosted by Reolysin in pancreatic cancer study

Last updated: 09:52 14 Apr 2016 EDT, First published: 04:52 14 Apr 2016 EDT

cancercell_570fa2e1530ef
Pancreatic cancer is one of the hardest strains of the disease to treat.

Oncolytics Biotech Inc (TSX:ONC) has claimed a clear improvement in survival rates in a phase II study for pancreatic cancer sufferers taking its Reolysin treatment.

Combined with carboplatin and paclitaxel, survival rates over two years in patients using Reolysin were significantly higher than control studies.

"These data clearly illustrate that patients receiving Reolysin whether in the test arm or crossing over after progressing in the control arm, received a benefit in longer-term overall survival," said Brad Thompson, executive chairman.

He added the results built on an earlier study were Reolysin and  gemcitabine combined also produced a clear longer-term overall survival benefit, despite having limited impact on progression free survival. 

“Based on these combined results, we are currently enrolling pancreatic cancer patients in a study incorporating Reolysin  plus the checkpoint inhibitor Keytruda  to determine the effect of the immune system on patient outcomes."

Pancreatic cancer is one of the hardest strains of the disease to treat.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

2 hours, 12 minutes ago